Abstract: Soluble IL-13 receptor alpha 1, or sIL13rα1, is a soluble protein that binds to 24 Interleukin 13 (IL-13) and that has been previously described in mice. The function of sIL13rα1 25 remains unclear, but it has been hypothesized to act as a decoy receptor for IL-13. Recent studies 26 have identified a role for IL-13 in glucose metabolism, suggesting that a decoy receptor for IL-13 27 might increase circulating glucose levels. Here we report that delivery of sIL13rα1 to mice by 28 either gene transfer or recombinant protein decreases blood glucose levels. Surprisingly, the 29 glucose-lowering effect of sIL13rα1 was preserved in mice lacking IL-13, demonstrating that IL- 
Interleukin 13 (IL-13) and that has been previously described in mice. The function of sIL13rα1 25 remains unclear, but it has been hypothesized to act as a decoy receptor for IL-13. Recent studies 26 have identified a role for IL-13 in glucose metabolism, suggesting that a decoy receptor for IL-13 27 might increase circulating glucose levels. Here we report that delivery of sIL13rα1 to mice by 28 either gene transfer or recombinant protein decreases blood glucose levels. Surprisingly, the 29 glucose-lowering effect of sIL13rα1 was preserved in mice lacking IL-13, demonstrating that IL-30 13 was not required for the effect. In contrast, deletion of IL-4 in mice eliminated the 31 hypoglycemic effect of sIL13rα1. In humans, endogenous blood levels of IL13rα1 varied 32 substantially, although there were no differences between diabetic and non-diabetic patients. 33 There was no circadian variation of sIL13rα1 in normal human volunteers. Delivery of sIL13rα1 34 fused to an FC domain provided sustained glucose lowering in mice on a high fat diet, 35 suggesting a potential therapeutic strategy. These data reveal sIL13rα1 as a circulating human 36 protein with an unexpected role in glucose metabolism. IL-13 is a member of the interleukin family, and IL-13 has diverse functions. signals through three distinct receptor complexes and binds with highest affinity to a heterodimer 41 receptor comprised of IL-4 receptor α and IL-13 receptor α-1 (3, 6). IL-13 is a central mediator 42 in bronchial asthma due to its role as an inducer of airway hyper-responsiveness and participates 43 in a variety of respiratory diseases including anaphylaxis, emphysema, and chronic obstructive 44 pulmonary disease (20, 22) . Recent studies have identified a role of IL-13 in regulating liver and 45 skeletal muscle metabolism (5, 19) . Interestingly, genetic deletion of IL-13 in mice leads to 46 hyperglycemia and upregulation of hepatic gluconeogenesis (19). IL-13 induces phosphorylation 47 of STAT-3, and loss of IL13rα1 in hepatocytes abolishes the inhibitory effects of IL-13 on 48 glucose production (19) . Collectively, these results suggest glycemic control is mediated through 49 the IL13rα1 receptor. 50 The presence of a soluble form of IL13rα1 (sIL13rα1) that binds to IL-13 in mice was 51 reported in 1997 (23). sIL13rα1 lacks the transmembrane domain of IL13rα1 and is produced 52 from alternative mRNA splicing that leads to early termination of translation (10). Since the 53 initial report of sIL13rα1, little research has been conducted to elucidate its function. One study 54 identified a role of sIL13rα1 in promoting B cell differentiation and maturation through possible 55 regulation of the IL-6R/gp130 complex (13). The existence of sIL13rα1 has yet to be reported in 56 humans (4) . Because sIL13rα1 has been shown to bind to IL-13, it is possible that sIL13rα1 can 57 inhibit IL-13 by acting as a decoy receptor. Given this function, we hypothesized that increasing 58 levels of sIL13rα1 would likely elevate blood glucose levels, similar to the phenotype observed 59 in mice with deletion of The kit was tested to assure assay linearity between 1-4 ng/ml in human serum and in 197 Statistical differences between vehicle and sIL13rα1 injection were assessed using 2-tailed 198 Student's t test. For in vitro assays, the mean and SEM were determined from 3-4 biological 199 replicates. A P value less than 0.05 was considered as significant. (Fig. 1A) . Fed glucose levels and body weights of animals 212 injected with sIL13rα1 AAVs were not significantly different from controls after one week. One 213 week after AAV administration, surprisingly, fasting blood glucose levels were significantly 214 lower in animals injected with sIL13rα1 AAV after a 6-hour fast (Fig. 1B) and an overnight fast 215 (Fig. 1C) .
216
To further characterize the effects of sIL13rα1 on glucose homeostasis, glucose tolerance 217 tests (GTT) and insulin tolerance tests (ITT) were performed. Mice with sIL13rα1 delivered by 218 AAV had improved glucose tolerance (Fig. 1D) as well as increased insulin sensitivity (Fig. 1E ).
219
Since we observed significant changes in glucose metabolism in mice treated with sIL13rα1 220 delivered by AAV, we measured if sIL13rα1 influences insulin secretion. No significant 221 differences were seen in fasting insulin levels between the treatment and control groups (Fig.   222   1F ). We then hypothesized that sIL13rα1 may decrease circulating glucose levels by acting on 223 the liver to inhibit gluconeogenesis. We performed pyruvate tolerance tests (PTT) to assess 224 whether sIL13rα1 might influence gluconeogenesis. The PTT suggested that sIL13rα1-treated 225 sIL13rα1 regulates fasting glucose levels 12 mice exhibited decreased glucose production (Fig. 1G) . When livers were harvested and the 226 expression of gluconeogenesis genes measured by qPCR, we observed significant decreases in 227 the expression of several key gluconeogenic genes in the sIL13rα1 AAV mice compared to the 228 null-AAV mice (Fig. 1H) To explore the role of sIL13rα1 on the regulation of fasting glucose levels, we expressed 232 and purified recombinant sIL13rα1 (sIL13rα1) protein with a baculovirus system ( Fig. 2A) . A 233 single injection of sIL13rα1 decreased glucose levels in fasting mice compared to vehicle-234 injected mice for nearly 24 hours, until the animals were fed again (Fig. 2B) . Similar to the mice 235 with sIL13rα1 delivered by AAV, we did not observe any differences in circulating insulin levels 236 between vehicle-and sIL13rα1-injected mice (1.40.14 ng/ml vs. 1.7 0.21 ng/ml; n=7).
237
Since we observed a decrease in expression of gluconeogenic genes in mice treated with 238 AAV expressing sIL13rα1, we repeated the PTT experiment in mice injected with recombinant 239 sIL13rα1 protein. Purified sIL13rα1 (or vehicle control) and pyruvate were injected after an 240 overnight fast. Glucose levels were significantly lower in the sIL13rα1-injected group compared 241 to controls (Fig. 2C) . In addition, livers were harvested and gluconeogenic gene expression was 242 measured by qPCR. Similar to the mice with sIL13rα1 delivered by AAV, mice injected with 243 recombinant sIL13rα1 had decreased expression of gluconeogenic genes (Fig. 2D) (Fig. 3A) . Serum sIL13rα1 levels were the same between the two groups ( Fig.   253 3B), revealing that sIL13rα1 reduces fasting glucose levels in a manner that is independent of IL- abolished this effect (Fig. 3C ). Serum levels of sIL13rα1 were similar (Fig. 3D) (Fig. 4A ) and in the skeletal muscle (Fig. 4B) (Fig. 4C) . Furthermore, we measured the expression of gluconeogenic genes in the livers of 274 wildtype and IL-4 -/-mice injected with either vehicle or sIL13rα1 (Fig. 4D) . In sIL13rα1-injected 275 mice, we observed a significant decrease in glucose-6-phosphatase catalytic subunit (G6pc) and 276 peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1α) mRNA 277 expression in wildtype mice, while no change was observed in IL4-/-mice (Fig. 4D ).
278
To test if sIL13rα1 can directly enhance IL-4 activity, primary hepatocytes were isolated 279 from rats. Hepatocytes were isolated, cultured, and treated with different concentrations of IL -4 280 (0.5ng/ml, 1ng/ml, 5ng/ml, 10ng/ml, 25ng/ml and 50ng/ml). Treatment with 1ng/ml of IL- 4 281 significantly enhanced STAT-6 phosphorylation but did not reach plateau (maximal) levels.
282
Hepatocytes were further treated with recombinant sIL13rα1 (300 ng/ml), IL-4 (1ng/ml), or both (Fig. 4E ).
287
Human levels of sIL13rα1 are similar in diabetic and non-diabetic patients.
288
The existence of a soluble form of IL13rα1 has been described previously only in mice 289 (23). In order to assess sIL13rα1 in humans, we used an ELISA system to measure sIL13rα1. We 290 first measured serum levels of sIL13rα1 in diabetic patients (n=148) (Table 1) . In this 584 patient study, there were no differences between diabetic patients, with 298 2.86 +/-26.38 ng/ml (mean +/-standard deviation) and non-diabetic patients with 2.92 +/-28.39 299 in sIL13rα1 levels ng/ml (mean +/-standard deviation). Furthermore, additional analyses of the 300 SOLID cohort stratifying by obesity and there was no evidence for an interaction (p=0.54) , 301 n=207 obese subjects (BMI >= 30 ), n=373 non-obese subjects (BMI < 30). Accounting for 302 obesity using conditional regression the relationship with sIL13rα1 remained non-significant 303 (p=0.84).
304
Because IL-13 levels have been reported to vary in a circadian manner (17), we also 305 measured if there was a circadian variation to sIL13rα1 levels in normal human volunteers.
306
Blood samples were collected from 24 healthy adults (mean age 22.1 ± 2.3 years, range 18-30) 307 who participated in an inpatient circadian rhythm study. The plasma sIL13rα1 levels for males 308 were not significantly different from females (1.31 ± 1.52 ng/ml vs. 1.24 ± 1.08 ng/ml, mean +/-309 standard deviation, p = 0.89), and there was no apparent variation in sIL13rα1 levels across a 40-310 hour sample collection period where the participants were in constant conditions.
311
We further determined the levels of the sIL13rα1serum levels in the high fat diet (HFD) mouse 312 model compared to the regular diet, and there was no significance difference between the groups 313 with 1.19 +/-0.09 ng/ml (n=8; mean +/-standard error) with the regular diet and with 1.30 +/-314 0.06 ng/ml in the HFD group (n=10; mean +/-standard error). Also, the serum levels of 315 sIL13rα1 were similar after an overnight fast and after feeding (1.08 +/-0.06 ng/ml vs. significantly lower in FC-IL13rα1-injected mice compared to vehicle (Fig. 5A ). The glucose 326 lowering effect was significant for five days post injection (Fig. 5B) , until circulating sIL13rα1 327 levels in FC-IL13rα1-injected mice fell (Fig. 5C) 
